RT Journal Article SR Electronic T1 Prognostic Relevance of the Proliferation Marker REPP86 for Laryngeal Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3541 OP 3547 VO 30 IS 9 A1 CHRISTIAN CORDES A1 ANN-KRISTIN MÜNZEL A1 TIBOR GÖRÖGH A1 IVO LEUSCHNER A1 PETRA AMBROSCH A1 STEFAN GOTTSCHLICH A1 MARKUS HOFFMANN YR 2010 UL http://ar.iiarjournals.org/content/30/9/3541.abstract AB Background: There is a clear correlation between proliferative activity and the biological behavior of cancer, which might have an impact on the patients' prognosis and consequences for the individual therapy concept. REPP86 (restrictedly expressed proliferation-associated protein 86) is a proliferation-associated protein expressed in S-, G(2)- and M-phases of the cell cycle, regarded as a promising proliferation marker and has not yet been examined in squamous cell carcinoma of the larynx (SCCL). Materials and Methods: REPP86 was analyzed retrospectively in 104 SCCL using the monoclonal antibody Ki-S2. Proliferative activity was correlated with tumor stage, histopathological grading, patients' survival and the results we recently published on Ki-67 staining in SCCL. Median follow-up time was 47 months. Results: A significant correlation (p<0.05) between histopathological grading, N-status and proliferation activity was observed. The patient group consisting of low proliferating laryngeal cancer showed a statistically longer absolute (p<0.05) and relapse-free (p=0.001) 5-year survival time than the group with a high proliferating tumor. Compared to the Ki-67 staining results, the REPP86 antibody better predicts the relapse-free 5-year-survival. Conclusion: Our results indicate that REPP86 staining of SCCL with Ki-S2 is a helpful prognostic indicator for SCCL and better predicts the relapse-free survival than Ki-67 staining in SCCL.